FindTrial
Sign In

Single-blind randomized control trial identify the effectiveness of electroconvulsive therapy (ECT) for patients with acute schizophrenia

Single-blind randomized control trial to evaluate the effectiveness of electroconvulsive therapy (ECT) in acute schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2019/010
Enrollment
Unknown
Registered
2019-03-11
Start date
2019-03-11
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute schizophrenia

Interventions

Study setting: Inpatient psychiatric units of the North Colombo Teaching Hospital Ragama and National Institute of Mental Health, Angoda Method of Randomization: Block Randomization Intervention ar

Sponsors

Sri Lanka Medical Association
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged 18-60 years 2. Schizophrenia diagnosed by a consultant psychiatrist according to DSM-V criteria 3. Positive and Negative Syndrome Scale (PANSS) score >75 . 4. Patients who have not responded adequately to inpatient treatments in medication for 10 days 5. Patients who remain psychotic and disturbed after 10 days of treatment

Exclusion criteria

Exclusion criteria: 1. Any contraindication for ECT (including medical conditions, raised intracranial pressure etc.) 2. Patients with prominent mood symptoms 3. Patients who are either dependent or have harmful use of psychoactive substances (alcohol or illicit drugs) 4. Patients who are non-compliant with medication 5. Any contraindication for general anaesthesia (including medical conditions) 6. The patients who are pregnant and lactating 7. Patients who do not have the capacity to give informed consent

Design outcomes

Primary

MeasureTime frame
To assess the change in mental illness severity using the Positive and Negative Syndrome Scale (PANSS) [Timepoint: weekly during the inpatient period and at week 1 and week 5 after discharge] To assess the effect of illness on the participant’s day-to-day life on the Global Assessment of Functioning Scale (GAF) [Timepoint: weekly during the inpatient period and at week 1 and week 5 after discharge] To assess the change in cognition as determined by the Montreal Cognitive Assessment (MoCA) [Timepoint: weekly during the inpatient period and at week 1 and week 5 after discharge]—

Secondary

MeasureTime frame
None []—

Countries

Sri Lanka

Contacts

Public ContactDr. Asiri Rodrigo

Lecturer and Consultant Psychiatrist

asirir2000@yahoo.comTel: +94-112961115

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026